Myfortic

Myfortic Overdosage

mycophenolic acid

Manufacturer:

Novartis Healthcare

Distributor:

Zuellig
Full Prescribing Info
Overdosage
There have been anecdotal reports of deliberate or accidental overdoses with Mycophenolic acid (Myfortic), whereas not all patients experienced related adverse events.
In those overdose cases in which adverse events were reported, the events fall within the known safety profile of the class. Accordingly an overdose could possibly result in oversuppression of the immune system and may increase the susceptibility to infection including opportunistic infections, fatal infections and sepsis. If blood dyscrasias occur (e.g. neutropenia with absolute neutrophil count <1.5 x 103/microL or anemia) it may be appropriate to interrupt or discontinue Mycophenolic acid (Myfortic) (see Precautions and Adverse Reactions).
Although dialysis may be used to remove the inactive metabolite MPAG, it would not be expected to remove clinically significant amounts of the active moiety MPA. This is in large part due to the very high plasma protein binding of MPA, 97%. By interfering with enterohepatic circulation of MPA, bile acid sequestrants, such as cholestyramine, may reduce the systemic MPA exposure.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in